Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Yearly Archives: 2024

You are here:
  1. Home
  2. 2024

A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patients

2024By Alexis BERNARDMay 7, 2024

07/05/2024 – AB Science today announced the publication of an article in Muscle & Nerve, a peer-reviewed medical journal covering neuromuscular medicine

The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

2024By Alexis BERNARDMay 2, 2024

02/05/2024 – AB Science announced today that the Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

AB Science announces a slight delay in the publication of its 2023 annual financial report

2024By Alexis BERNARDApril 30, 2024

30/04/2024 – The Company will publish its annual financial report no later than May 15, 2024

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS

2024By Alexis BERNARDApril 3, 2024

03/04/2024 – AB Science today announces that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS)

New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

2024By Alexis BERNARDMarch 13, 2024

13/03/2024 – AB Science today announced the publication of new preclinical results for masitinib in neurodegenerative diseases

Summary of the live webcast held on March 4, 2024, providing an update on AB Science development

2024By Alexis BERNARDMarch 7, 2024

07/03/2024 – AB Science is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development

Two financial analysis firms initiate coverage of AB Science

2024By Alexis BERNARDMarch 6, 2024

06/03/2024 – AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

AB Science webcast of March 4, 2024

2024By Alexis BERNARDMarch 4, 2024

04/03/2024 – Presentation of the AB Science webcast held on March 4, 2024

Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

2024By Alexis BERNARDMarch 1, 2024

01/03/2024 – AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALS

2024By Alexis BERNARDFebruary 26, 2024

26/02/2024 – AB Science today announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)

←1234→
AB Science
© AB Science – All right reserved
Go to Top